Status:
COMPLETED
Alemtuzumab and Cyclosporine for the Prevention of Graft vs Host Disease After Stem Cell Transplants
Lead Sponsor:
University Health Network, Toronto
Collaborating Sponsors:
Bayer
Conditions:
Graft Versus Host Disease
Bone Marrow Transplantation
Eligibility:
All Genders
16-70 years
Phase:
PHASE2
Brief Summary
Graft versus host disease (GVHD) is one of the common complications after stem cell transplant. This is a complication, which happens when the new stem cells from the donor attack other cells in the b...
Eligibility Criteria
Inclusion
- Diagnosis of a hematological malignancy
- Peripheral blood as source of stem cells
- Able to give informed consent
- Availability of 6/6 matched sibling donor
- Fit for transplant using a conventional or reduced intensity approach
Exclusion
- AST/ALT \>3 x IULN at the time of transplant
- Serum creatinine \> 1.5 x IULN at the time of transplant
- Prior allogeneic transplant
- Syngeneic donor
- Active uncontrolled infection
- HIV positive
- Pregnancy at the time of BMT
Key Trial Info
Start Date :
October 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2010
Estimated Enrollment :
78 Patients enrolled
Trial Details
Trial ID
NCT00775632
Start Date
October 1 2008
End Date
September 1 2010
Last Update
June 23 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Princess Margaret Hospital
Toronto, Ontario, Canada, M5G 2M9